KENDALL MELENDI: Open Payments
NPI 1508479411 · ST PETERSBURG, FL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,074 in 36 payments from 13 companies in 2025. Trend: 2023 $2,274 · 2024 $2,506 · 2025 $1,074
Food & beverage: $1,074
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 4 | $187 |
| Botanix SB Inc | 8 | $184 |
| Galderma Laboratories, L.P. | 7 | $174 |
| UCB, Inc. | 2 | $165 |
| GENZYME CORPORATION | 3 | $98 |
| Lilly USA, LLC | 3 | $78 |
| MAYNE PHARMA COMMERCIAL LLC | 2 | $43 |
| Organon LLC | 2 | $32 |
| Regeneron Healthcare Solutions, Inc. | 1 | $29 |
| E.R. Squibb & Sons, L.L.C. | 1 | $24 |
Products named: SOFDRA, NEMLUVIO, Bimzelx, RINVOQ, DUPIXENT, EBGLYSS, SKYRIZI, VTAMA.
Industry payments across FL — which companies pay providers there.
